Treatment of bipolar disorder: New perspectives

References

• Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005; 7: 424–30
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006; 67(Suppl 9)25–30
   Google Scholar
• Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001; 58: 844–50
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh S, Macqueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7(Suppl 3)5–69
   PubMed Web of Science ®Google Scholar
• Kruger S, Young LT, Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord. 2005; 7: 205–15
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59: 530–7
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003; 60: 261–9
   PubMed Web of Science ®Google Scholar
• Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000; 157: 124–6
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10: 323–33
   PubMed Web of Science ®Google Scholar
• Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep. 2006; 8: 478–88
   PubMedGoogle Scholar
• Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67(Suppl 11)22–7
   Google Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003; 17: 149–73
   PubMed Web of Science ®Google Scholar
• Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2007; 8: 4–11
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH. Relapse prevention in bipolar disorder: a critical review of current guidelines. J Psychopharmacol. 2006; 20: 12–6
   Google Scholar
• Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007; 9: 394–412
   PubMed Web of Science ®Google Scholar
• Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998; 18: 455–60
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005; 62: 996–1004
   PubMed Web of Science ®Google Scholar
• Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003; 60: 904–12
   PubMed Web of Science ®Google Scholar
• Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006; 188: 313–20
   PubMed Web of Science ®Google Scholar
• Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949; 2: 349–51
   PubMed Web of Science ®Google Scholar
• Garnham J, Munro A, Slaney C, MacDougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: Results of a naturalistic observation study. J Affect Disord. 2007; 104: 185–90
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disord. 2000; 2: 3–7
   PubMed Web of Science ®Google Scholar
• Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004; 14(Suppl 2)S94–9
   PubMedGoogle Scholar
• Young LT, Cooke RG, Robb JC, Levitt AJ, Joffe RT. Anxious and non-anxious bipolar disorder. J Affect Disord. 1993; 29: 49–52
   PubMed Web of Science ®Google Scholar
• Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000; 157: 956–62
   PubMed Web of Science ®Google Scholar
• Henry C, Van den Bulke D, Bellivier F, Etain B, Rouillon F, Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J Clin Psychiatry. 2003; 64: 331–5
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Szadoczky E, Furedi J, Kiss K, Papp Z. Anxiety disorders comorbidity in bipolar I, bipolar II and unipolar major depression: results from a population-based study in Hungary. J Affect Disord. 2001; 67: 175–9
   PubMedGoogle Scholar
• Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry 1993; 163(Suppl 21)16–9
   Google Scholar
• Duffy A, Grof P, Robertson C, Alda M. The implications of genetic studies of major mood disorders for clinical practice. J Clin Psychiatry. 2000; 61: 630–7
   PubMed Web of Science ®Google Scholar
• Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord. 1994; 32: 85–95
   PubMed Web of Science ®Google Scholar
• Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait?. J Clin Psychiatry. 2002; 63: 942–7
   PubMed Web of Science ®Google Scholar
• Duffy A, Alda M, Kutcher S, Cavazzoni P, Robertson C, Grof E, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry. 2002; 63: 1171–8
   PubMed Web of Science ®Google Scholar
• MacKinnon DF, Zandi P, Cooper J, Potash JB, Simpson SG, Gershon E, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry. 2002; 159: 30–5
   PubMed Web of Science ®Google Scholar
• Potash JB, Zandi PP, Willour VL, Lan TH, Huo Y, Avramopoulos D, et al. Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry. 2003; 160: 680–6
   PubMed Web of Science ®Google Scholar
• Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry. 2000; 48: 531–8
   PubMed Web of Science ®Google Scholar
• Passmore M, Garnham J, Duffy A, MacDougall M, Munro A, Slaney C, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003; 5: 110–4
   PubMed Web of Science ®Google Scholar
• Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile?. Can J Psychiatry. 2007; 52: 369–76
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatr Res. 1987; 21: 71–83
   PubMed Web of Science ®Google Scholar
• Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007; 7: 9–16
   PubMedGoogle Scholar
• Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42(Suppl 1)2–10
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Pies R. Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry. 2003; 15: 203–16
   PubMedGoogle Scholar
• Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998; 32: 255–9
   PubMed Web of Science ®Google Scholar
• Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 2001; 1: 71–7
   PubMedGoogle Scholar
• Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007; 62: 1295–302
   PubMed Web of Science ®Google Scholar
• Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrzak-Weglarz M, et al. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry. 2006; 7: 158–61
   PubMed Web of Science ®Google Scholar
• Sjoholt G, Ebstein RP, Lie RT, Berle JO, Mallet J, Deleuze JF, et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry. 2004; 9: 621–9
   PubMedGoogle Scholar
• Silberberg G, Levit A, Collier D, St Clair D, Munro J, Kerwin RW, et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics. 2008; 18: 403–12
   Google Scholar
• Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol. 2006; 9: 83–8
   Google Scholar
• Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003; 64(Suppl 5)53–61
   PubMedGoogle Scholar
• Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 2005; 7: 1–10
   PubMed Web of Science ®Google Scholar
• Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006; 7: 1421–34
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, Blond SY, Fedolak A, et al. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc. 2007; 129: 8328–32
   Google Scholar
• Einat H, Manji HK. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 2006; 59: 1160–71
   Google Scholar
• Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry. 2004; 65: 10–21
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004; 161: 171–4
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005; 57: 430–2
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007; 61: 822–5
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47: 351–4
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63: 856–64
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006; 93: 105–15
   PubMed Web of Science ®Google Scholar
• Emilien G, Septien L, Brisard C, Corruble E, Bourin M. Bipolar disorder: how far are we from a rigorous definition and effective management?. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 975–96
   Google Scholar
• Atre-Vaidya N, Taylor MA, Seidenberg M, Reed R, Perrine A, Glick-Oberwise F. Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol. 1998; 11: 120–6
   PubMedGoogle Scholar
• Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Torrent C, et al. Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology 2002; 46(Suppl1)16–21
   Google Scholar
• Laes JR, Sponheim SR. Does cognition predict community function only in schizophrenia?: a study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr Res. 2006; 84: 121–31
   Google Scholar
• Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord. 2005; 7: 216–35
   PubMed Web of Science ®Google Scholar
• Hoschl C, Hajek T. Hippocampal damage mediated by corticosteroids—a neuropsychiatric research challenge. . Eur Arch Psychiatry Clin Neurosci 2001; 251(Suppl 2)II81–8
   PubMed Web of Science ®Google Scholar
• Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry. 1999; 46: 1595–602
   PubMed Web of Science ®Google Scholar
• Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry. 2003; 54: 693–702
   PubMed Web of Science ®Google Scholar
• Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol Psychiatry. 2000; 48: 1–8
   PubMed Web of Science ®Google Scholar
• Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000; 356: 1241–2
   PubMed Web of Science ®Google Scholar
• Yucel K, McKinnon MC, Taylor VH, Macdonald K, Alda M, Young LT, et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl) 2007; 195: 357–67
   PubMedGoogle Scholar
• Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 2007; 9: 183–96
   PubMed Web of Science ®Google Scholar
• Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry. 1993; 150: 720–7
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998; 155: 646–52
   PubMed Web of Science ®Google Scholar
• Tohen M, Hennen J, Zarate CM, Jr, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000; 157: 220–8
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry. 2002; 63: 807–11
   PubMed Web of Science ®Google Scholar
• Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA. 1992; 267: 1478–83
   PubMed Web of Science ®Google Scholar
• Clark L, Iversen SD, Goodwin GM. Sustained attention deficit in bipolar disorder. Br J Psychiatry. 2002; 180: 313–9
   PubMed Web of Science ®Google Scholar
• Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006; 29: 657–61
   PubMed Web of Science ®Google Scholar
• Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003; 163: 205–9
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007; 68: 899–907
   PubMed Web of Science ®Google Scholar
• Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord. 2002; 68: 167–81
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007; 68: 917–23
   PubMed Web of Science ®Google Scholar
• Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry. 2006; 67: 1034–41
   PubMed Web of Science ®Google Scholar
• Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. Diabetologia. 2007; 50: 431–8
   PubMed Web of Science ®Google Scholar
• Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004; 25: 471–80
   PubMed Web of Science ®Google Scholar
• Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001; 104: 163–72
   PubMed Web of Science ®Google Scholar
• Ahrens B, Muller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord. 1995; 33: 67–75
   PubMed Web of Science ®Google Scholar
• Grof P, Alda M. Discrepancies in the efficacy of lithium. Arch Gen Psychiatry. 2000; 57: 191
   PubMed Web of Science ®Google Scholar